Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...
Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a ...
With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...
Clinical-stage biotech Aktis Oncology (AKTS), which counts Eli Lilly (LLY) among its partners, traded sharply higher after ...
Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...
Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...
Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not ...
Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...
No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...
Aktis Oncology, Inc. (NASDAQ: AKTS) IPO will take place January, 09 on the NASDAQ exchange under the ticker AKTS. The company ...
Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...
Backed by Eli Lilly, Aktis Oncology's $318M IPO marks 2026's first major biotech public offering, signaling renewed investor ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback